Physician profile
Jennifer Mitchell
NPI 1861106023
$3,482.89
in general payments reported to CMS, 2019-2025
21 companies · $1,394 in 2025
The $1,394 reported for 2025 was more than what 87% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $890 · 2024: $1,199 · 2025: $1,394.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,483.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,482.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $410.09 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $395.76 | 2023-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $350.79 | 2024-2025 | Caplyta |
| Axsome Therapeutics, INC. | $343.08 | 2023-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $339.97 | 2024-2025 | Spravato, Invega Sustenna |
| Corium, LLC | $246.43 | 2023-2025 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $210.37 | 2023-2025 | Uzedy |
| Takeda Pharmaceuticals U.S.A., INC. | $169.32 | 2023-2025 | Trintellix |
| Supernus Pharmaceuticals, INC. | $167.03 | 2023-2025 | Qelbree, Qelbree |
| Bausch Health US, LLC | $154.99 | 2023-2025 | Wellbutrin, Aplenzin |
| E.R. Squibb & Sons, L.L.C. | $116.50 | 2025 | Cobenfy |
| Alkermes, INC. | $113.63 | 2024 | Lybalvi |
| Collegium Pharmaceutical, INC. | $95.74 | 2025 | Jornay Pm |
| Neurocrine Biosciences, INC. | $81.21 | 2025 | |
| Ironshore Pharmaceuticals INC. | $65.32 | 2023-2024 | Jornay Pm |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $62.65 | 2025 | Dyanavel Xr |
| Noven Therapeutics, LLC | $59.25 | 2025 | Xelstrym, Secuado |
| Vanda Pharmaceuticals INC. | $34.62 | 2025 | Fanapt |
| Vertical Pharmaceuticals, LLC | $32.61 | 2025 | Relexxii |
| Harmony Biosciences LLC | $19.54 | 2024 | |
| Idorsia Pharmaceuticals US INC | $13.99 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.